Behçet’s disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to protean inflammatory involvement of multiple organs and tissues. Treatment has been revolutionized by the progressed knowledge in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6. However, although biological treatment with anti-TNF-α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time. Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. Different agents targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and the B-lymphocyte antigen CD-20 by rituximab. The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF-α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium.

1. Introduction

Behçet’s disease (BD) is a chronic and relapsing multisystemic inflammatory disorder which can be localized on the borderline between autoimmune and autoinflammatory diseases [1]. Its incidence is increased around the Mediterranean basin, extending through Middle East and Orient countries, and from a clinical point of view the disorder is mainly characterized by recurrent episodes of mucocutaneous, ocular, joint, vascular, and central nervous system involvement. Recurrent oral and/or genital aphthosis, ocular involvement in terms of uveitis and, retinal vasculitis in combination with variable skin lesions are the cardinal signs of BD [2]. Considerable heterogeneity has been observed.
among different cohorts of patients with BD, with life-threatening arterial and venous vessel inflammation and thrombotic complications. Furthermore, although somewhat less frequently, BD patients may show joint, gastrointestinal, peripheral, and central nervous system and renal, cardiac, and pulmonary involvement [3]. Its etiology remains still unknown, but the most accredited hypothesis suggests a complex interaction between genetic background and environmental factors, such as microbial agents or their antigens (related to herpes simplex virus, streptococci, staphylococci, or Escherichia species) [4]. Human leukocyte antigen (HLA)-B 51, one of the numerous split antigens of HLA-B 5, is the strongest genetic marker of BD in different ethnic groups, as reported both in genome wide association [5, 6] and in meta-analysis studies [7–9]. Although HLA-B 51’s mode of action is unclear, antigen presentation ability, molecular mimicry with microbial antigens, or participation in linkage disequilibrium with other genes has been suggested as potential contributive mechanisms in the pathogenesis of BD [7–9]. However, major pathogenetic mechanisms underlying BD are linked to innate immune cell activation and dysregulation, and hyperactivity of neutrophils, T-helper (Th) 1, and Th-17 natural killer (NK) cells, the main result of which is the critical overproduction of proinflammatory cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL-) 1β, IL-6, and IL-17 [10]. Our improved understanding of the molecular mechanisms involved in BD has recently opened up new interesting scenarios in terms of therapy, which might be initiated in the most severely affected patients to avoid complications, such as vascular thrombosis and neurological and/or ocular manifestations [3]. Prior to the introduction of biological agents, options for the treatment of severe BD were limited. In particular, TNF inhibition was successful in controlling inflammation in many patients [11]. However, not all patients responded to different anti-TNF-α agents, and loss of efficacy did also appear over time in patients initially responding to anti-TNF biological drugs. Recently many reports have begun to describe BD patients in whom molecular targets other than TNF were sought [12]. The aim of this review is to summarize all current experience and evidence about a new therapeutic biological approach in BD with drugs other than TNF-α blockers.

2. Cornerstones of Treatment in Behçet’s Disease

BD clinical course is highly irregular and erratic, ranging from simple localized mucocutaneous symptoms, that may or may not be associated with uveitis, to severe forms associated with eye and neurological involvement linked to less favourable outcomes. Thus, therapy is mainly based on the type and severity of clinical manifestations and disease duration, as well as number of flares [15]. The mainstay of therapy of isolated aphthosis and acne-like lesions is centred on topical measures [14]. Colchicine at a daily dosage of 1-2 mg/day can be introduced as an additional option in the management of mucocutaneous signs, as its efficacy has been demonstrated in genital aphthosis and erythema nodosum, as well as in joint involvement displayed by female patients [15, 16]. However, data on oral aphthosis and pseudofolliculitis are controversial [15–17], and azathioprine may be considered in cases with severe resistant mucocutaneous and articular involvement [13]. Indeed, azathioprine, usually administered at a daily dosage of 2.5 mg/kg, has been shown to positively impact the long-term prognosis and frequency of mucocutaneous and articular manifestations of BD [18, 19]. Azathioprine importance lies in its beneficial effects on the posterior uveitis [18]. In particular, in a two-year randomized controlled trial in Turkish males with BD, both without and with eye involvement, azathioprine induced a decrease in uveitis flares and protected against the recurrence of uveitis [19]. Thus, its use along with systemic corticosteroids is recommended in BD patients showing eye involvement affecting the posterior segment [13]. In addition to azathioprine, cyclosporine A, at a daily dosage of 5 mg/kg, has also shown its efficacy on the ocular posterior involvement, bringing about improvement in visual acuity during the first 6 months of therapy [20]. Its efficacy at a dosage of 10 mg/kg daily has been demonstrated at a short-term follow-up, with reduction in both frequency and severity of ocular flares [21]. However, these dosages cannot be considered in long-term treatment due to the risk of secondary nephropathy, hypertension, and neurotoxicity [13]. In addition to azathioprine and cyclosporine A, other immunosuppressive drugs currently used in the management of BD include thalidomide [22], methotrexate [23], and cyclophosphamide [24]. The absence of consolidated data on the efficacy of methotrexate and thalidomide in BD keeps them from being recommended as definite therapeutic strategies [13], although thalidomide has been shown to be potentially useful in the management of severe gastrointestinal involvement prior to implementation of other strategies and surgery [13]. Thalidomide, at the daily dosage ranging from 100 to 300 mg, has also been shown to reduce the frequency of orogenital ulcerations and pseudofolliculitis, but, due to the teratogenic risk and frequent peripheral polyneuropathy, its use is limited [22]. The efficacy of methotrexate, usually employed at a dosage of 7.5–15 mg once a week, has been reported just in one observational study related to posterior uveitis [25]. Efficacy of cyclophosphamide has been proved in patients with ocular, vascular, and neurological involvement [24, 26–30]. With regard to ocular involvement, in a recent study, eye outcomes were evaluated after long-term administration of cyclophosphamide (1 g pulse of cyclophosphamide monthly for 6 months and then every 2-3 months as necessary), azathioprine (at a daily dosage of 2-3 mg/kg), and prednisolone (initiated at 0.5 mg/kg daily and tapered in case of remission) in 295 patients: total adjusted disease activity index significantly improved, but improvement of visual acuity was unremarkable, due to the onset of secondary cataracts [24]. Early use of cyclophosphamide (at a daily dosage of 1 mg/kg given per os or at a dosage ranging from 750 to 1 g/m² every 4 weeks given intravenously) has been considered useful for the vascular complications of BD, including thromboses, occlusions, and large-vessel aneurysms, among the most feared complications due to high potential morbidity and mortality
risk [26–29]. Patients with severe neurological clinical signs (meningoencephalitis, dural sinus thrombosis, and severe peripheral nervous system involvement) also require high-dose oral or intravenous corticosteroids in association with cyclophosphamide, at a dosage based on the severity and location of inflammation [30]. For severe and relapsing BD a broad spectrum of therapies consisting of interferon [31] and intravenous immunoglobulins [32] are available, but efficacy data are limited and conflicting [31–33]. To date, therapy has been revolutionized by advances in the knowledge of BD pathogenetic mechanisms, namely, dysfunction and oversecretion of a network of proinflammatory molecules, principally TNF-α [10, 34]. Data on anti-TNF-α agents are derived from BD case reports and series of patients who were resistant to immunosuppressants and corticosteroids, most of whom suffered from ocular, gastrointestinal, neurological, and vascular manifestations [35–38]. Among anti-TNF-α agents, etanercept, a fusion protein of the TNF receptor and IgG1 Fc domain, has been shown to reduce the frequency of oral aphthosis and skin lesions combined with a moderate improvement of joint manifestations [35].

Infliximab, a chimeric mouse-human anti-TNF-α monoclonal antibody, at a dosage of 5 mg/kg in combination with an immunosuppressive agent, has induced a rapid remission of eye refractory inflammatory signs [39]. Additionally, infliximab, combined with corticosteroids and/or immunosuppressive agents such as cyclosporine A or azathioprine, may be an option in nonemergency cases of gastrointestinal involvement, while its efficacy in patients with parenchymal involvement of the central nervous system is needs to be further evaluated [40–42]. Adalimumab, a humanized IgG1 monoclonal anti-TNF-α antibody, has been effective in relieving ocular involvement of BD, in particular when patients lost efficacy to infliximab [36].

In the management of gastrointestinal involvement, prior to surgery, sulfasalazine, corticosteroids, azathioprine, thalidomide, and anti-TNFα agents should be employed [13]. With regard to ocular involvement, anterior uveitis can be responsive to topical low-dose steroids, while patients with retinal vasculitis, macular involvement, or severe uveitis, defined as a >2-line drop in visual acuity on a 10/10 scale, require azathioprine along with corticosteroids administered orally (prednisone at a daily dosage of 1 mg/kg) or intravenously (methylprednisolone at a daily dosage of 1 g for 3 days), combined with cyclosporine A or infliximab. Corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide are recommended in the management of acute deep vein thrombosis [28, 29]. With regard to the management of central nervous system involvement, corticosteroid therapy is recommended for dural sinus thrombosis, while a combination therapy of corticosteroids with azathioprine, cyclophosphamide, methotrexate, anti-TNF-α agents, and interferon may all be considered in cases of meningoencephalitis [13].

3. Rationale and Methods

There is currently no gold standard therapy for BD, and increasing evidence of molecular and cellular pathways involved in its pathogenesis continues to emerge. Recent data have spread the promising therapeutic targets other than TNF in patients with severe and refractory BD (Figure 1). Therefore, we reviewed the available medical literature to find all cases of BD treated with biological agents other than TNF-inhibitors, using the PubMed database. We matched the following search terms: “Behcet’s” and “anakinra,” “canakinumab,” “gevokizumab,” “tocilizumab,” “ustekinumab,” and “rituximab,” in order to find studies,
including case reports and case series, showing all current experiences and the most recent evidence regarding these novel therapeutic approaches in BD.

4. Results

We found 44 cases of BD patients in therapy with biological agents other than anti-TNF-α agents. In particular, we found eight studies, describing 24 patients on IL-1 inhibitors [12, 43–50], 13 treated with the IL-1β receptor antagonist anakinra [12, 43, 44, 47, 48], 4 with the IL-1 blocker canakinumab [46, 49, 50], and 7, described in one open-label pilot study, with the anti-IL-1 agent gevokizumab [45] (Table 1). Additionally, 7 patients were described being treated with the IL-6 receptor antagonist tocilizumab [51–56], just 1 case with the anti-IL-12/23R agent ustekinumab [57] (Table 2), and 12 with the anti-CD-20 agent rituximab [58–60] (Table 3).

4.1. Interleukin-1 Inhibition and Behcet's Disease. The IL-1 superfamily comprises a group of II cytokines which regulate many intracellular signaling pathways: IL-1α and IL-1β are the most studied members, binding their receptor type I (IL-1RI) and coreceptor-accessory protein (IL-1RACP). While IL-1α is expressed as a precursor and is constitutively present in most cells of healthy subjects, IL-1β, induced by several cytokines as TNF-α, IL-18, IL-1α, and IL-1β itself, is mainly produced by monocytes, tissue macrophages, fibroblasts, and dendritic cells [61]. IL-1β is the principal proinflammatory cytokine, leading to the expression of many chemokines and secondary mediators of inflammation and upregulating innate immunity in response to infectious agents [61]. The inactive precursor of IL-1β requires cleavage by an intracellular cysteine protease, called caspase-1, which must be activated to convert IL-1β into its bioactive form [61]. The proinflammatory effects of IL-1 are due to the binding with IL-1RI and IL-1RACP, which together form a heterotrimeric signalling-competent complex; additionally, IL-1β autinduction represents an aspect of the autoinflammation that characterizes many autoinflammatory disorders [62, 63]. IL-1β involvement in BD is mainly linked to the evidence of elevated amounts of IL-1β in the sera of patients with BD and to the fact that IL-1β inhibition has induced a stable clinical remission in different reports [61, 63–65]. Among the available IL-1 blockers, the IL-1 receptor antagonist anakinra, as well as canakinumab and gevokizumab, targeting the IL-1 molecule directly, has been used in patients with BD and provided encouraging preliminary data on the successful IL-1 inhibition, leading to an increased interest in anti-IL-1 agents for managing BD [61, 63]. Anakinra is a recombinant human IL-1 receptor antagonist that competes with IL-1α and IL-1β and thus inhibits the proinflammatory effects of both cytokines: it has been approved for use in rheumatoid arthritis (at a recommended dose of 100 mg/day subcutaneously) and has been used off-label for a broad spectrum of inflammatory conditions, bringing about a sustained disease remission [61, 63]. In 2008 Botzios et al. reported one BD patient presenting with fever, mucocutaneous involvement, colon ischemic perforation, thrombosis, seerosis, and elevated inflammatory markers for whom infliximab was withdrawn due to onset of mucosal abdominal abscesses: anakinra (at the dosage of 100 mg/day) was then started in association with prednisolone (5 mg/day), leading to complete remission in only one week [43]. Two years later Bilginer et al. reported a complete positive response to anakinra (1 mg/kg/day) in a febrile patient diagnosed with familial Mediterranean fever and BD showing mucocutaneous involvement, arthritis, and secondary amyloidosis [44]. Recently, Emmi et al. reported the efficacy of anakinra (100 mg/day) in a patient with mucosal, skin, joint, ocular, and gastrointestinal involvement, in whom a combination of anti-TNF agents and rituximab resulted inefficacious. In this case, a complete positive response was reported at the 12-month followup visit [47]. Additionally, we have recently reported the efficacy of anakinra (100 mg/day) in a patient with BD associated with sacroiliitis, in whom infliximab lost its efficacy despite a concomitant high dosage of prednisone (50 mg/day). Complete remission was verified within a few days, and prednisone was tapered to 5 mg/day without any relapses [48]. Recently, our group has also reported on nine BD patients on anakinra: seven out of nine patients responded to 100 mg/day of anakinra, but two showed no improvement. In six of the seven patients, responses to anakinra were rapid (obtained within 1-2 weeks). Additionally, three out of four patients suffering from recurrent uveitis showed a complete resolution of ocular inflammation. Orogenital aphthosis and skin lesions were the most frequent manifestations refractory to anakinra, with a poor response in seven out of nine patients. In order to control mucocutaneous manifestations, colchicine was successfully introduced in three patients. Thrombotic lesions during treatment with anakinra occurred in two patients, and two others developed retinal vasculitis after 8 months while were on anakinra [12]. In the end, one of two refractory patients achieved complete resolution by increasing the anakinra dose to 150 mg/day. Canakinumab is a human monoclonal IgG that selectively neutralizes IL-1β, inhibiting its binding to IL-1RI and all cytokine-dependent signaling pathways: the half-life is 21–28 days, and recommended dose is 2 mg/kg subcutaneously in children or 150 mg subcutaneously in adults every 8 weeks. Its safe and successful use has been demonstrated in cryopyrin-associated periodic syndromes and systemic-onset juvenile idiopathic arthritis [61, 63]. Canakinumab administered as monotherapy has also recently been shown to be efficacious in refractory BD, confirming that inhibition of the proinflammatory effects of IL-1β is paramount in controlling the clinical spectrum of BD [50]. Additionally, our recent study has suggested that canakinumab given every 6 weeks may be a suitable monodrug therapeutic option for BD patients, confirming the prompt resolution of all disease-related clinical manifestations without any adverse event [50]. Just one patient, previously reported in 2012 when on canakinumab at a dosage of 150 mg every 8 weeks [49], relapsed while was on this dosage, requiring a shorter interval between canakinumab administrations [50]: when canakinumab was administered at the same dosage every 6 weeks a successful response was again obtained, with a stable recovery of patient's clinical picture [50]. One of these patients was also unresponsive to anakinra but
| First author (reference, year) | N pts | Clinical and laboratory features | HLA-B51 | Previous biologic agents and causes of withdrawal | Dosage and eventual cotherapies | Followup | Outcome |
|--------------------------------|-------|----------------------------------|---------|-----------------------------------------------|-------------------------------|---------|---------|
| Botsios (2008) [43]           | 1     | Fever, mucosal involvement, colon ischemic perforation, necrotizing lymphocytic venulitis, thrombosis, serositis, increase of inflammatory markers, and SPR | Negative | IFX: mucosal abdominal abscesses | ANA 100 mg/day + PDN 5 mg/day | 20 months | CR and improvement of inflammatory markers in 7–10 days. Disease-free at 20-month followup |
| Bilginer (2010) [44]          | 1     | Fever, mucosal involvement, EN, arthritis, secondary amyloidosis, increase of inflammatory markers, and SPR overlapping with FMF | NR | None | ANA 1 mg/kg/day | 18 months | CR and improvement of inflammatory markers; patient free of clinical symptoms at 18-month followup; however proteinuria gradually increased (from 1.8 to 2.4 g/day) |
| Gül (2012) [45]               | 7     | Acute posterior or panuveitis and/or retinal vasculitis | NR | None | GEV: 0.3 mg/kg (single infusion) | Up to disease relapse | Improvement in visual acuity from day 1 in 5 out of 7 patients. Complete resolution of retinal findings achieved in 4–21 days (median 14 days). No detailed assessments of extraocular manifestations were performed. Recurrence of folliculitis and oral aphtosis. Median duration of response: 49 days (range: 21–97 days) |
| Ugurlu (2012) [46]            | 1     | Mucosal involvement, EN, bilateral panuveitis, retinal vasculitis, and SPR | NR | INF-γ: fever; IFX and ANA: flares of uveitis; ADA: loss of efficacy | CAN 150 mg (single dose) | 8 weeks | CR for 8 weeks; resolution of ocular inflammation and rapid VA improvement. |
| Emni (2013) [47]              | 1     | Mucosal and gastrointestinal involvement, arthritis, pseudofolliculitis, and bilateral retinal vasculitis | NR | IFX: ADR (diffuse urticaria with angioedema); ADA and RTX: persistent uveitis | ANA 100 mg/day | 12 months | CR after 12 months of followup; rapid and persistent disappearance of joint pain, mucocutaneous and bowel manifestations; VA improvement, clearing of the vitreous opacity and no active retinal inflammation |
Table 1: Continued.

| First author (reference, year) | N pts | Clinical and laboratory features | HLA-B51 | Previous biologic agents and causes of withdrawal | Dosage and eventual cotherapies | Followup | Outcome |
|-------------------------------|-------|---------------------------------|---------|-----------------------------------------------|-------------------------------|----------|---------|
| Cantarini (2013) [12]         | 9     | Mucosal involvement, EN, headache, retinal vasculitis, low-back pain, and increase of inflammatory markers | Positive | ETN and IFX; loss of efficacy | ANA 150 mg/day + PDN 25 mg/day + colchicine 1 mg/day | 9 months | PR; PDN was reduced to 7.5 mg/day |
|                               |       | Fever, mucosal involvement, skin lesions, headache, arthritis, abdominal pain, and increase of inflammatory markers | Positive | None | ANA 100 mg/day | 19 months | CR at 12-month followup; onset of DVT after 16 months; CR at 28-month followup |
|                               |       | Fever, mucosal involvement, skin lesions, headache, and increase of SAA | Positive | ANA (100 mg/day): inefficacy | ANA 150 mg/day + PDN 25 mg/day | 19 months | DVT not resolved with heparin at 6 months; CYC (5 mg/kg/day) was added; CR with reduction of SAA at 18 months |
|                               |       | Mucosal involvement, bilateral panuveitis, retrobulbar optic neuritis, papillophlebitis, headache, arthralgia, DVT, and increase of SAA | Positive | ETN: loss of efficacy | ANA 100 mg/day + PDN 12.5 mg/day | 6 months | Flare of panuveitis after 3 months; ANA was withdrawn. CR with ADA (40 mg twice monthly) + MTX (10 mg/weekly) + PDN (25 mg/day) |
|                               |       | Fever, mucosal involvement, EN, headache, arthritis, papillophlebitis, pseudofolliculitis, and increase of SAA | Positive | None | ANA 100 mg/day + AZA 50 mg/day + PDN 7.5 mg/day | 8 months | CR after 12 months |
|                               |       | Mucosal involvement, skin lesions, abdominal pain, photophobia, and increase of inflammatory markers | Positive | ADA: inefficacy | ANA 2 mg/kg/day + PDN 15 mg/day | 9 months | Flare of uveitis after 8 months; ANA was increased to 150 mg/day + MTX (15 mg/weekly) + colchicine (1 mg/day); PR at 17 months of followup |
|                               |       | Fever, mucosal involvement, venous thrombosis, arthritis, panuveitis, headache, pseudofolliculitis, and increase of ESR and SAA | Positive | None | ANA 100 mg/day | 12 months | CR at first; relapse after 4 months requiring an increased dosage of ANA (2.5 mg/kg/day); PR after 7 months |
|                               |       | Mucosal involvement, skin lesions, abdominal pain, photophobia, and increase of SAA | Positive | ADA: inefficacy | ANA 100 mg/day + PDN 10 mg/day | 6 months | PR; CYC (5 mg/kg/day) was added after 8 months of followup |
|                               |       | Fever, mucosal involvement, EN, arthritis, anterior uveitis, pseudofolliculitis, and increase of CRP | Positive | None | ANA 100 mg/day + PDN 10 mg/day | 6 months | Inefficacy after 8 weeks; CAN (150 mg every 8 weeks) was started with PR after 2 weeks |
|                               |       | Fever, mucosal and gastrointestinal involvement, headache, anterior uveitis, and arthralgia | Positive | ETN and ADA: loss of efficacy | ANA 100 mg/day | 9 months | Inefficacy after 8 weeks; CAN (150 mg every 8 weeks) was started with PR after 2 weeks |
| Caso (2014) [48]              | 1     | Mucosal and ocular involvement, pseudofolliculitis, sarcoiditis, and increase of inflammatory markers | Positive | IFX: loss of efficacy | ANA 100 mg/day + PDN 50 mg/day | 12 months | CR in few days; PDN was tapered to 5 mg/day |
| First author  | N pts | Clinical and laboratory features                              | HLA-B51 | Previous biologic agents and causes of withdrawal                                                                 | Dosage and eventual cotherapies | Followup | Outcome                               |
|---------------|-------|----------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------------------------|---------------------------------|----------|---------------------------------------|
| Cantarini (2012) [49] | 3     | Fever, mucosal involvement, skin lesions, arthritis, abdominal pain, headache, and increase of inflammatory markers and SAA overlapping with granuloma annulare | Positive | SSZ, MTX, CYC, AZA and LFN: inefficacy; ETN: ADR (recurrent urinary tract infections and bacterial endocarditis); IFX: ADR (recurrent urinary tract infections); ANA: ADR (urticarial lesions) | CAN 150 mg every 8 weeks       | 16 months | CR in few months; DVT after 16 months; heparin was started and CAN dosing interval was shortened to 6 weeks; CR after 6 months of followup |
| Vitale (2014) [50] |       | Fever, mucosal and gastrointestinal involvement, headache, anterior uveitis, and arthralgia | Positive | ETN and ADA: loss of efficacy; ANA: inefficacy | CAN 150 mg every 6 weeks | 12 months | CR after few months                  |
|               |       | Fever, mucosal involvement, DVT, panuveitis, headache, arthritis, pseudofolliculitis, and increase of ESR and SAA | Positive | ANA: ADR (urticarial skin lesions) | CAN 150 mg every 6 weeks | 6 months | CR within few days                   |

Abbreviations: ADA: adalimumab; ADR: adverse reactions; ANA: anakinra; AZA: azathioprine; BD: Behcet's disease; CAN: canakinumab; CYC: cyclosporine; CMO: cystoid macular oedema; CR: complete remission; CRP: C-reactive protein; CS: corticosteroids; DVT: deep venous thrombosis; EN: erythema nodosum; ESR: erythrocyte sedimentation rate; ETN: etanercept; FMF: familial Mediterranean fever; GEV: gevokizumab; HLA: human leukocyte antigen; Ig: immunoglobulin; IFX: infliximab; INF-γ: interferon-gamma; LFN: leflunomide; MTX: methotrexate; N: number; NR: not reported; pts: patients; PDN: prednisone; PR: partial remission; RTX: rituximab; SAA: serum amyloid-A; SPR: skin pathergy reaction; SSZ: sulfasalazine; VA: visual acuity.
| First author (reference, year) | N pts | Main BS clinical and laboratory features | HLA-B51 | Previous biologic agents with causes of withdrawal | Dosage and eventual cotherapies | Followup | Outcome |
|--------------------------------|-------|------------------------------------------|--------|-------------------------------------------------|-------------------------------|----------|---------|
| Hirano (2012) [51]           | 1     | Mucosal involvement, EN, and uveitis     | NR     | IFX: loss of efficacy                              | TCZ 8 mg/kg every 4 weeks     | 12 months | VA improvement and resolution of EN and genital aphthosis. Partial improvement of oral aphthosis |
| Shapiro (2012) [52]           | 1     | Mucosal and neurologic involvement, bilateral uveitis, and cutaneous vasculitis | NR     | IFX: concomitant onset of IgA nephropathy         | TCZ 8 mg/kg every 4 weeks + PDN 30–60 mg/day | 7 months | CR after the 2nd infusion; PDN was tapered off; complete resolution of ocular, neurological, and skin manifestations; oral ulcers recurred |
| Urbaniak (2012) [53]          | 1     | Mucosal and neurologic involvement, EN, DVT, and thrombophlebitis | NR     | IFX: worsening of the gait disturbance and relapse of myelitis | TCZ 8 mg/kg every 4 weeks + AZA 150 mg/day + PDN 1 mg/kg/day | 8 months | Improvement of clinical signs and symptoms; after the 4th infusion TCZ was discontinued due to a scrotal abscess |
| Caso (2013) [54]              | 1     | Fever, mucosal involvement, myalgia, bilateral uveitis, optic neuritis, EN, SPR, and increase of inflammatory markers overlapping with refractory pemphigus foliaceus | Positive | IFX and ADA: inefficacy; ANA: loss of efficacy | TCZ 480 mg every 4 weeks | 14 months | CR with improvement of inflammatory markers within few days |
| Redondo-Pachón (2013) [55]    | 1     | Mucosal involvement, EN, iridocyclitis, secondary amyloidosis, and increase of CRP | Positive | None | TCZ 8 mg/kg every 4 weeks + colchicine 1 mg/day | 12 months | CR with decrease of proteinuria and CRP after the 2nd infusion |
| Diamantopoulos (2013) [56]    | 2     | Mucosal involvement, pseudofolliculitis, and cutaneous vasculitis | NR     | IFX and ETN: short efficacy and ADR (not specified) | TCZ 8 mg/kg every 4 weeks + AZA 150 mg/day | Unknown | Inefficacy; worsening of mouth and genital ulcers |
| Mucosal involvement, increase of inflammatory markers | NR | IFX and ADA: incomplete response and ADR (not specified) | | TCZ 8 mg/kg every 4 weeks | 3 months | Initial PR with loss of efficacy after the 3rd infusion; recurrence of genital ulcers |
| Baerveldt (2013) [57]         | 1     | Mucosal involvement, anterior uveitis, arthritis, and pathergy reaction overlapping with psoriasis vulgaris and hidradenitis suppurativa | NR     | None | Ustekinumab 45 mg at weeks 0 and 4 and every 12 weeks | 36 months | CR within few months, clinical improvement of psoriasis |

ADA: adalimumab; ADR: adverse reactions; ANA: anakinra; AZA: azathioprine; BD: Behçet's disease; CR: complete remission; CRP: C-reactive protein; DVT: deep venous thrombosis; EN: erythema nodosum; ETN: etanercept; HLA: human leukocyte antigen; IFX: infliximab; MRI: magnetic resonance imaging; MTX: methotrexate; N: number; NR: not reported; pts: patients; PDN: prednisone; PR: partial remission; TCZ: tocilizumab; VA: visual acuity.
Table 3: Studies reporting on patients with Behçet’s disease treated with anti-CD20 monoclonal antibody (rituximab).

| First author (reference, year) | N pts | Main BD clinical and laboratory features | HLA-B51 | Previous biologic agents and causes of withdrawal | Dosage and eventual cotherapies | Followup | Outcome |
|--------------------------------|------|----------------------------------------|---------|-----------------------------------------------|--------------------------------|----------|---------|
| Sadreddini (2008) [58]        | 1    | Mucosal involvement, arthritis, posterior uveitis, retinal vasculitis, and chronic renal failure (of unknown origin) | NR      | RTX 1 g every two weeks for two doses + PDN 1 mg/kg/day | 24 months | CR of retinal vasculitis within few months and PDN was tapered to 5 g/day |
| Davatchi (2010) [59]          | 10   | Mucosal, ocular, and articular involvement; skin manifestations | NR      | RTX 1 g every two weeks for two doses + PDN 0.5 mg/kg/day + MTX 15 mg/week | 6 months | Improvement of ocular manifestations after 6 months. TADAI significant improvement on RTX. VA improved in two patients, remained unchanged in 1, and worsened in 7. Significant improvement of retinal, disc, and macular oedema in all patients |
| Zhao (2014) [60]              | 1    | Fever, mucosal involvement, arthritis, EN, leukocytoclastic vasculitis, increase of CRP | NR      | RTX 1 g every two weeks for two doses + PDN 15 mg/day + MTX 20 mg/week + colchicine | 12 months | CR after the 3rd infusion; improved clinical control of disease activity and reduction in steroids requirements (PDN tapered to 8 mg/day) |

ADR: adverse reactions; BD: Behçet's disease; CR: complete remission; CRP: C-reactive protein; EN: erythema nodosum; ETN: etanercept; HLA: human leukocyte antigen; IFX: infliximab; MTX: methotrexate; N: number; NR: not reported; pts: patients; PDN: prednisone; RTX: rituximab; TADAI: total adjusted disease activity index; VA: visual acuity.
took advantage from canakinumab with complete resolution of intraocular inflammation, fever, abdominal pain, and headache within 2 weeks from the start of canakinumab [50]. An additional case related to treatment of BS with canakinumab has recently been published by Ugurlu et al. In this report a single dose of 150 mg of canakinumab was effective in inducing a sustained resolution of BD clinical manifestations, even the ocular ones, and in normalizing all inflammation markers within a few weeks, after that infliximab, adalimumab, and anakinra were all ineffective [46].

Gevokizumab is a recombinant humanized anti-IL-1β antibody, that modulates IL-1β bioactivity by reducing the affinity for its IL-1RI:IL-1RACP signaling complex [61]; it has recently been evaluated in BD patients with refractory uveitis. Further convincing evidence of IL-1β role in BD derives from a trial based on gevokizumab in patients with multiresistant and sight-threatening uveitis: following a single intravenous infusion of gevokizumab (at the dosage of 0.3 mg/kg) there was a rapid complete resolution of intraocular inflammation along with marked improvement in visual acuity within 21 days. In addition, five patients who were retreated with gevokizumab for recurrent uveitis responded to a second dose and maintained their response for several months, despite discontinuation of immunosuppressive agents and without the need to increase steroid dosage [45].

4.2. Interleukin-6 Inhibition and Behcet’s Disease. IL-6 is a pleiotropic cytokine secreted by various cell types, including T and B lymphocytes, macrophages, osteoblasts, fibroblasts, keratinocytes, and endothelial cells, involved in many immune pathways and playing a pivotal role in the regulation of various immune responses, in the amplification of acute inflammation, and in its progression into relapsing or chronic inflammatory reactions [66]. Increased plasma IL-6 levels have been reported in patients with BD, mainly in those showing evidence of neurologic involvement, suggesting a correlation with disease activity [67]. Tocilizumab is a humanized monoclonal antibody which specifically inhibits IL-6 by competitively blocking the binding site to the IL-6 receptor, definitely approved for patients with rheumatoid arthritis refractory to traditional disease-modifying antirheumatic drugs. However, due to the IL-6 effects on immune system and inflammatory processes, IL-6 antagonism is now considered a potential therapeutic strategy even in various autoinflammatory and autoimmune disorders [68, 69]. Seven BD patients treated with tocilizumab have been reported [51–56]; all presented orogenital manifestations and six of them cutaneous involvement; ocular involvement was reported in four patients [51, 52, 54, 55], and one of these also suffered from optic neuritis [54]. The reported dosage of tocilizumab was 8 mg/kg every 4 weeks [51–53, 55, 56] or, alternatively, 480 mg every 4 weeks [54]. Tocilizumab monotherapy was used in three cases and brought about complete remission in two [51, 54], while in the third it lost efficacy after the third infusion [56]. Efficacy of tocilizumab was also reported in combination with corticosteroids and other drugs in other two patients [52, 53]. In particular, it is noteworthy that complete remission under tocilizumab was reported in combination with high-dose corticosteroids [52, 53]: in the first case prednisone was used in a dose range of 30–60 mg once daily [52], while in the second prednisone was used at the dosage of 1 mg/kg/day in combination with azathioprine; however, in the second case tocilizumab was discontinued after the fourth infusion due to the occurrence of a scrotal abscess due to Escherichia coli [53]. Another BD patient with secondary amyloidosis, treated with colchicine and tocilizumab, showed also a complete remission and decreased proteinuria [55]. However, in another patient the combination of tocilizumab and azathioprine was ineffectual in the treatment of mucocutaneous manifestations [56]. Notably, among BD patients successfully treated with tocilizumab, six had failed to respond to anti-TNF agents [51–54, 56] and one of these became resistant to anakinra and other traditional immunosuppressive drugs [54].
with repeated courses decided on the individual clinical evaluation) [81]. Rituximab off-label use has been increasing in recent years for other immune-mediated diseases [82–84], as well as for BD [58–60].

In a single-blind randomized controlled trial related to 20 patients with refractory BD involving the eye, 10 patients were treated with rituximab (1 g × 2/infusions, 2 weeks apart) and methotrexate (15 mg/week) and 10 with cyclophosphamide (monthly intravenous infusions of 1000 mg), azathioprine (2-3 mg/kg/day), and prednisone (0.5 mg/kg/day): rituximab and methotrexate were found to be more effective than traditional drugs in improving all the most dreadful ocular manifestations [59]. Moreover, another BD patient with retinal vasculitis refractory to azathioprine and corticosteroids and intolerant to etanercept was successfully treated with rituximab (at the dosage of 1 g given intravenously every two weeks) combined with prednisone (15 mg/day), methotrexate (20 mg/week) and colchicine: this treatment was successful after the third rituximab infusion, allowing a progressive reduction in the corticosteroid dosage [60].

5. Conclusive Remarks

The final goal in the treatment strategies of BD is to prevent irreversible multisystemic damage: an ideal therapy should be tailored according to the extent and severity of BD heterogeneous clinical manifestations [11, 13]. Because of the possibility of failure of traditional immunosuppressive and anti-TNF agents, there is need for alternative therapeutic tools with other modes of action, particularly for refractory cases of BD. Based on recurrent inflammatory attacks, lack of autoantibodies, and response to IL-1 inhibition in some patients [12], BD could be depicted as a peculiar autoinflammatory disorder; on the other hand, BD shares with the autoimmune diseases the possibility of being treated with immunosuppressive agents, and therapeutic benefit observed in patients treated with interferon supports the hypothesis of a Th1-driven disease [85]. Although BD classification as an autoinflammatory or autoimmune disorder is still a matter of debate [1, 86, 87], the response to specific novel therapies could provide clinical insights into the causal basis of the syndrome. Multiple cytokines likely contribute to BD pathological landscape, and it is doubtful that blocking a single cytokine or a specific cell line will resolve all of the protein disease manifestations [34]. Among the newer therapies studied to date, inhibition of IL-1β, IL-6, and CD20 seems to show the best results. Convincing evidence of IL1β role in BD derives from a trial of gevokizumab in patients with multiresistant uveitis [45] and from the successful experience with anakinra [12, 43, 44, 47, 48] and canakinumab [46, 49, 50], while the increasing number of published reports of BD patients treated with tocilizumab [51–56] and rituximab [58–60] demonstrates the complex heterogeneous biochemical scenery behind this syndrome. However, the number of patients on these therapies is still low, making it difficult to draw firm and definite conclusions. Therefore, further large controlled studies involving BD patients and longer-term follow-up periods are needed to corroborate these recent observations and confirm the efficacy and safety of these treatments, which provide a valuable addition to the current therapeutic armamentarium in refractory BD.

Conflict of Interests

Luca Cantarini received grant/research support from Novartis, SOBI, where he serves as consultant.

Authors’ Contribution

Francesco Caso and Luisa Costa equally contributed to the present paper.

References

[1] D. Rigante, “The fresco of autoinflammatory diseases from the pediatric perspective,” Autoimmunity Reviews, vol. 11, no. 5, pp. 348–356, 2012.
[2] International Study Group for Behçet's disease, “Criteria for diagnosis of Behçet's disease,” The Lancet, vol. 335, pp. 1078–1080, 1990.
[3] D. Saadoun and B. Wechsler, “Behçet's disease,” Orphanet Journal of Rare Diseases, vol. 7, no. 1, article 20, 2012.
[4] H. Direskeneli, “Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51,” Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 996–1002, 2001.
[5] E. F. Remmers, F. Cosan, Y. Kirino et al., “Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease,” Nature Genetics, vol. 42, no. 8, pp. 698–702, 2010.
[6] Y. Kirino, G. Bertsias, Y. Ishigatsu et al., “Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1,” Nature Genetics, vol. 45, no. 2, pp. 202–207, 2013.
[7] C. Maldini, M. P. Lavalle, M. Cheminant, M. de menthon, and A. Mahr, “Relationships of HLA-B51 or B5 genotype with Behçet’s disease clinical characteristics: systematic review and meta-analyses of observational studies,” Rheumatology, vol. 51, no. 5, pp. 887–900, 2012.
[8] M. Piga and A. Mathieu, “Genetic susceptibility to Behçet’s disease: role of genes belonging to the MHC region,” Rheumatology, vol. 50, no. 2, Article ID keq331, pp. 299–310, 2011.
[9] M. De Menthon, M. P. LaValley, C. Maldini, L. Guillevin, and A. Mahr, “HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies,” Arthritis Care and Research, vol. 61, no. 10, pp. 1287–1296, 2009.
[10] M. Pintelon de Chambrun, B. Wechsler, G. Geri, P. Cacoub, and D. Saadoun, “New insights into the pathogenesis ofBehçet’s disease,” Autoimmunity Reviews, vol. 11, no. 10, pp. 687–698, 2012.
[11] G. Hatemi, A. Silman, D. Bang et al., “Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1528–1534, 2009.
Mediators of Inflammation

[12] L. Cantarini, A. Vitale, P. Scalini, C. A. Dinarello, D. Rigante, R. Franceschini et al., “Anakinra treatment in drug-resistant Behçet’s disease: a case series,” *Clinical Rheumatology*, 2013.

[13] G. Hatemi, A. Silman, D. Bang et al., “EULAR recommendations for the management of Behçet disease;” *Annals of the Rheumatic Diseases*, vol. 67, no. 12, pp. 1656–1662, 2008.

[14] S. R. Dalvi, R. Yıldırım, and Y. Yazıcı, “Behçet’s syndrome,” *Drugs*, vol. 72, no. 17, pp. 2223–2241, 2012.

[15] E. Aktulga, M. Altaç, A. Müftuoğlu, Y. Ozyazgan, H. Pazarli, Y. Tüzün et al., “A double blind study of colchicine in Behçet’s disease,” *Haematologica*, vol. 65, pp. 399–402, 1980.

[16] S. Yurdakul, C. Mat, Y. Tüzün, Y. Ozyazgan, V. Hamuryudan, O. Uysal et al., “A double-blind trial of colchicine in Behçet’s syndrome,” *Arthritis & Rheumatology*, vol. 44, pp. 2686–2692, 2001.

[17] F. Davatchi, B. Sadeghi Abdollahi, A. Tahmani Banihashemi et al., “Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial,” *Modern Rheumatology*, vol. 19, no. 5, pp. 542–549, 2009.

[18] V. Hamuryudan, Y. Ozyazgan, N. Hızlı, C. Mat, S. Yurdakul, Y. Tüzün et al., “Azathioprine in Behçet’s syndrome: effects on long-term prognosis,” *Arthritis & Rheumatology*, vol. 40, pp. 769–774, 1997.

[19] H. Yazıcı, H. Pazarli, C. G. Barnes, Y. Tüzün, Y. Ozyazgan, A. Silman et al., “A controlled trial of azathioprine in Behçet’s syndrome,” *The New England Journal of Medicine*, vol. 322, pp. 281–285, 1990.

[20] Y. Ozyazgan, S. Yurdakul, H. Yazıcı, B. Tüzün, A. İşçi, Y. Tüzün et al., “Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial;” *British Journal of Ophthalmology*, vol. 76, pp. 241–243, 1992.

[21] K. Masuda, A. Nakajima, A. Urayama, K. Nakae, M. Kogure, and G. Inaba, “Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease;” *The Lancet*, vol. 1, no. 8647, pp. 1093–1096, 1989.

[22] V. Hamuryudan, C. Mat, S. Saipt et al., “Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial,” *Annals of Internal Medicine*, vol. 128, no. 6, pp. 443–450, 1998.

[23] F. Davatchi, H. Shams, F. Shahram et al., “Methotrexate in ocular manifestations of Behçet’s disease: a longitudinal study up to 15 years;” *International Journal of Rheumatic Diseases*, vol. 16, no. 5, pp. 568–577, 2013.

[24] F. Davatchi, B. Sadeghi Abdollahi, H. Shams, F. Shahram, A. Nadji, C. Chams-Davatchi et al., “Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behçet’s disease: longitudinal study of up to 10 years;” *International Journal of the Rheumatic Diseases*, 2013.

[25] F. Davatchi, F. Shahram, H. Chams et al., “High dose methotrexate for ocular lesions of Behçet’s disease. Preliminary short-term results;” *Advances in Experimental Medicine and Biology*, vol. 528, pp. 579–584, 2003.

[26] V. Hamuryudan, S. Yurdakul, F. Moral, F. Numan, H. Tüzün, N. Tüzün et al., “Pulmonary arterial aneurysms in Behçet’s syndrome: a report of 24 cases;” *British Journal of Rheumatology*, vol. 33, pp. 48–51, 1994.

[27] V. Hamuryudan, T. Er, E. Seyahi, C. Akman, H. Tüzün, I. Fresko et al., “Pulmonary artery aneurysms in Behcet syndrome;” *The American Journal of Medicine*, vol. 117, pp. 867–870, 2004.

[28] E. Kural-Seyahi, I. Fresko, N. Seyahi et al., “The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center;” *Medicine*, vol. 82, no. 1, pp. 60–76, 2003.

[29] K. T. Calamia, M. Schirmer, and M. Melikoglu, “Major vessel involvement in Behçet’s disease: an update;” *Current Opinion in Rheumatology*, vol. 23, no. 1, pp. 24–31, 2011.

[30] A. Al-Araji and D. P. Kidd, “Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management,” *The Lancet Neurology*, vol. 8, no. 2, pp. 192–204, 2009.

[31] I. Köttér, M. Zierhut, A. K. Eckstein et al., “Human recombinant interferon α2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis;” *British Journal of Ophthalmology*, vol. 87, no. 4, pp. 423–431, 2003.

[32] N. Seider, I. Beiran, J. Scharf, and B. Miller, “Intravenous immunoglobulin therapy for resistant ocular behçet’s disease;” *British Journal of Ophthalmology*, vol. 85, no. 11, pp. 1287–1288, 2001.

[33] E. Alpsoy, C. Durusoy, E. Yilmaz et al., “Interferon α2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study;” *Archives of Dermatology*, vol. 138, no. 4, pp. 467–471, 2002.

[34] Z. Y. Zhou, S. L. Chen, N. Shen, and Y. Lu, “Cytokines and Behcet’s Disease;” *Autoimmunity Reviews*, vol. 11, no. 10, pp. 699–704, 2012.

[35] M. Melikoglu, I. Fresko, C. Mat et al., “Interferon α2a in Behcet’s disease: a double blind, placebo controlled study;” *Journal of Rheumatology*, vol. 32, no. 1, pp. 98–105, 2005.

[36] D. Perra, M. A. Alba, J. L. Callejas, M. Mesquida, R. Ríos-Fernández, A. Adán et al., “Adalimumab for the treatment of Behçet’s disease: experience in 19 patients;” *Rheumatology (Oxford)*, vol. 51, pp. 1825–1831, 2012.

[37] P. P. Sifakis, P. H. Kaklamanis, A. Elezoglou et al., “Infliximab for recurrent, sight-threatening ocular inflammation in adamiatiades-Behçet disease;” *Annals of Internal Medicine*, vol. 140, no. 5, pp. 404–406, 2004.

[38] M. Mesquida, M. Victoria Hernández, V. Llorenç, L. Pelegrín, G. Espinosa, A. D. Dick et al., “Behçet disease-associated uveitis successfully treated with golimumab;” *Ocular Immunology and Inflammation*, vol. 21, pp. 160–162, 2013.

[39] F. Cantini, L. Niccoli, C. Nannini et al., “Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients;” *Biologics: Targets and Therapy*, vol. 6, pp. 5–12, 2012.

[40] S. Iwata, K. Saito, K. Yamaoka et al., “Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease;” *Modern Rheumatology*, vol. 21, no. 2, pp. 184–191, 2011.

[41] N. Pipitone, I. Olivieri, A. Padula et al., “Infliximab for the treatment of neuro-Behçet’s disease: a case series and review of the literature;” *Arthritis Care and Research*, vol. 59, no. 2, pp. 285–290, 2008.

[42] A. Borhani Haghhighi, A. Safari, M. A. Nazarinia, Z. Habibagahi, and S. Shenavandeh, “Infliximab for patients with neuro-Behçet’s disease: case series and literature review;” *Clinical Rheumatology*, vol. 30, no. 7, pp. 1007–1012, 2011.

[43] C. Botisios, P. Sfriso, A. Furlan, L. Punzi, and C. A. Dinarello, “Resistant Behçet disease responsive to anakinra;” *Annals of Internal Medicine*, vol. 149, no. 4, pp. 284–286, 2008.

[44] Y. Bilginer, N. A. Ayaz, and S. Ozen, “Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet’s disease;” *Clinical Rheumatology*, vol. 29, no. 2, pp. 209–210, 2010.
A. Gül, I. Tugal-Tutkun, C. A. Dinarello et al., “Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study,” *Annals of the Rheumatic Diseases*, vol. 71, no. 4, pp. 563–566, 2012.

S. Ugurlu, D. Ucar, E. Seyahi, G. Hatemi, and S. Yurdakul, “Canakinumab in a patient with juvenile Behçet’s syndrome with refractory eye disease,” *Annals of the Rheumatic Diseases*, vol. 71, no. 9, pp. 1589–1591, 2012.

G. Emmi, E. Silvestri, A. M. Cameli, D. Bacherini, L. Vannozzi, D. Squarrito et al., “Anakinra for resistant Behçet uveitis: why not?” *Clinical and Experimental Rheumatology*, vol. 31, pp. 152–153, 2013.

F. Caso, D. Rigante, A. Vitale, O. M. Lucherini, and L. Cantarini, “Efficacy of anakinra in refractory Behçet’s disease sacroiliitis,” *Clinical and Experimental Rheumatology*. In press.

L. Cantarini, A. Vitale, M. Borri, M. Galeazzi, and R. Franceschini, “Successful use of canakinumab in a patient with resistant Behçet’s disease,” *Clinical and Experimental Rheumatology*, vol. 30, no. 72, article SI15, 2012.

A. Vitale, D. Rigante, F. Caso, M. G. Brizi, M. Galeazzi, L. Costa et al., “Inhibition of interleukin-1β by canakinumab as a successful mono-drug strategy for the treatment of Behçet’s disease patients,” *Dermatology*, vol. 228, no. 3, 2014.

T. Hirano, N. Ohguro, S. Hohki et al., “A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab,” *Modern Rheumatology*, vol. 22, no. 2, pp. 298–302, 2012.

L. S. Shapiro, J. Farrell, and A. Borhani Haghhighi, “Tocilizumab treatment for neuro-Behçet’s disease, the first report,” *Clinical Neurology and Neurosurgery*, vol. 114, no. 3, pp. 297–298, 2012.

P. Urbaniačik, P. Hasler, and S. Kretzschmar, “Refractory neuro-Behçet treated by tocilizumab: a case report,” *Clinical and Experimental Rheumatology*, vol. 30, supplement 72, pp. S73–S75, 2012.

F. Caso, L. Iaccarino, S. Bettio et al., “Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab,” *Immunologic Research*, vol. 56, no. 2-3, pp. 390–397, 2013.

M. D. Redondo-Pachón, R. Enriquez, A. E. Sirvent, E. Andrada, R. Noguera-Pachón, I. Millán et al., “Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet’s disease,” *Renal Failure*, vol. 35, pp. 547–550, 2013.

A. P. Diamantopoulos and G. Hatemi, “Lack of efficacy of tocilizumab in mucocutaneous Behçet’s syndrome: report of two cases,” *Rheumatology (Oxford)*, vol. 52, pp. 1923–1924, 2013.

E. M. Baerwaldt, J. H. Kappen, H. B. Thio, J. A. M. Van Laar, P. Martin Van Hagen, and E. P. Prens, “Successful long-term triple disease control by ustekinumab in a patient with Behçet’s disease, psoriasis and hidradenitis suppurativa,” *Annals of the Rheumatic Diseases*, vol. 72, no. 4, pp. 626–627, 2013.

S. Sadreddini, H. Noshad, M. Molaeeard, and R. Noshad, “Treatment of retinal vasculitis in Behçet’s disease with rituximab,” *Modern Rheumatology*, vol. 18, no. 3, pp. 306–308, 2008.

F. Davatchi, H. Shams, M. Rezaipoor et al., “Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study),” *International Journal of Rheumatic Diseases*, vol. 13, no. 3, pp. 246–252, 2010.

B. H. Zhao and A. E. Oswald, “Improved clinical control of a challenging case of Behçet’s disease with rituximab therapy,” *Clinical Rheumatology*, vol. 35, pp. 149–150, 2014.

C. A. Dinarello and J. W. van der Meer, “Treating inflammation by blocking interleukin-1 in humans,” *Seminars in Immunology*, vol. 25, no. 6, pp. 469–484, 2013.

F. Caso, D. Rigante, A. Vitale, O. M. Lucherini, L. Costa, M. Atteno et al., “Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues,” *International Journal of Rheumatology*, vol. 2013, Article ID 513782, 15 pages, 2013.

M. Moll and J. B. Kuenenmer-Deschner, “Inflammassome and cytokine blocking strategies in autoinflammatory disorders,” *Clinical Immunology*, vol. 147, no. 3, pp. 242–275, 2013.

K. Hamzaoui, M. Hamaz, and K. Ayed, “Production of TNF-alpha and IL-1 in active Behçet’s disease,” *The Journal of Rheumatology*, vol. 17, pp. 1428–1429, 1990.

S. Pay, H. Erdem, A. Pekel et al., “Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1β play a major role in Behçet’s synovitis?” *Rheumatology International*, vol. 26, no. 7, pp. 608–613, 2006.

J. E. Fonseca, M. J. Santos, H. Canhão, and E. Choy, “Interleukin-6 as a key player in systemic inflammation and joint destruction,” *Autoimmunity Reviews*, vol. 8, no. 7, pp. 538–542, 2009.

G. Akman-Demir, E. Tüzün, S. Içöz, N. Yeşilot, S. P. Yentür, M. Kürttünçü et al., “Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome,” *Cytokine*, vol. 44, pp. 373–366, 2008.

P. M. Vaitla, P. M. Radford, P. J. Tighe et al., “Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome,” *Arthritis and Rheumatism*, vol. 63, no. 4, pp. 1151–1155, 2011.

R. S. Woodrick and E. M. Ruderman, “IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions,” *Bulletin of the NYU Hospital for Joint Diseases*, vol. 70, no. 3, pp. 195–199, 2012.

W. Chi, X. Zhu, P. Yang, X. Liu, X. Lin, H. Zhou et al., “Upregulated IL-23 and IL-17 in Behçet patients with active uveitis,” *Investigative Ophthalmology & Visual Science*, vol. 49, pp. 3058–3064, 2008.

K. Hamzaoui, A. Hamzaoui, F. Guemira, M. Bassioud, M. Hamza, and K. Ayed, “Cytokine profile in Behçet’s disease patients: relationship with disease activity,” *Scandinavian Journal of Rheumatology*, vol. 31, no. 4, pp. 205–210, 2002.

J. M. Xavier, F. Shahramp, F. Davatchi et al., “Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet’s disease,” *Arthritis & Rheumatism*, vol. 64, pp. 2761–2772, 2012.

N. Mizuki, A. Meguro, M. Ota et al., “Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci,” *Nature Genetics*, vol. 42, no. 8, pp. 703–706, 2010.

C. Parham, M. Chirica, J. Timans et al., “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R,” *Journal of Immunology*, vol. 168, no. 11, pp. 5699–5708, 2002.

A. Gottlieb, A. Menter, and A. Mendelsohn, “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis; randomised, double-blind, placebo-controlled, crossover trial,” *The Lancet*, vol. 373, pp. 633–640, 2009.

E. Eksioğlu-Demiralp, A. Kibaroglu, H. Direskeneli et al., “Phenotypic characteristics of B cells in Behçet’s disease: increased activity in B cell subsets,” *Journal of Rheumatology*, vol. 26, no. 4, pp. 826–832, 1999.
[77] C. H. Suh, Y. B. Park, J. Song, C. H. Lee, and S. K. Lee, "Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet’s disease," *Arthritis & Rheumatology*, vol. 44, pp. 1707–1712, 2001.

[78] A. Hamzaoui, H. Chelbi, F. H. Sassi, and K. Hamzaoui, "Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet’s disease with pulmonary involvement," *Oxidative Medicine and Cellular Longevity*, vol. 5, no. 2, pp. 122–128, 2010.

[79] S. Hirohata and H. Kikuchi, "Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behçet’s disease," *Clinical and Experimental Rheumatology*, vol. 27, pp. S91–S95, 2009.

[80] G. A. Leget and M. S. Czuczman, "Use of rituximab, the new FDA-approved antibody," *Current Opinion in Oncology*, vol. 10, no. 6, pp. 548–551, 1998.

[81] J. C. W. Edwards, L. Szczepański, J. Szechiński et al., "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis," *The New England Journal of Medicine*, vol. 350, no. 25, pp. 2572–2581, 2004.

[82] L. Andrade-Ortega, F. Irazoque-Palazuelos, S. Muñoz-López, and V. M. Rosales-Don Pablo, "Efficacy and tolerability of rituximab in patients with rhupus," *Reumatologia Clinica*, vol. 9, no. 4, pp. 201–205, 2013.

[83] F. Caso, U. Fiocco, L. Costa, P. Sfriso, L. Punzi, and A. Doria, "Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis," *Joint Bone Spine*, vol. 81, no. 2, pp. 190–192, 2014.

[84] J. I. Shin and M. Eisenhut, "A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion?" *Journal of Allergy and Clinical Immunology*, vol. 133, no. 2, article 600, 2014.

[85] I. Kötter, V. Hamuryudan, Z. E. Oztürk, and H. Yazıcı, "Interferon therapy in rheumatic diseases: state-of-the-art 2010," *Current Opinion in Rheumatology*, vol. 22, pp. 278–283, 2010.

[86] H. Direskeneli, "Autoimmunity vs autoinflammation in Behçet’s disease: do we oversimplify a complex disorder?" *Rheumatology*, vol. 45, no. 12, pp. 1461–1465, 2006.

[87] A. Vitale, D. Rigante, O. M. Lucherini et al., "Biological treatments: new weapons in the management of monogenic autoinflammatory disorders," *Mediators of Inflammation*, vol. 2013, Article ID 939847, 16 pages, 2013.
